Coram to Purchase Caremark's Home Infusion Therapy Business
DENVER--Coram Healthcare Corp. has reached a definitive agreement to acquire Caremark International's home infusion therapy business. Under the agreement, Caremark will receive approximately $310 million in cash and securities.
DENVER--Coram Healthcare Corp. has reached a definitive agreementto acquire Caremark International's home infusion therapy business.Under the agreement, Caremark will receive approximately $310million in cash and securities.
Articles in this issue
Selecting a Support Group for Patients With Prostate Carcinoma
Antman Provides Outlook on Use of High-Dose Chemo
Radiofrequency Ablation of Brain Tumors New Option
Oncologist Enthusiastic About Capitated Plan
Digital Mammography Has Potential to Detect Small Tumors, Increase Accuracy in Dense Breasts
GAO Says Federal Research Needed on Safety of Portable Cellular Telephones
Varmins Chooses New Director for NIH Office of Alternative Medicine
Identifying the 'Sentinel' Lymph Node May Obviate Need for Total Axillary Dissection
'Visible Man' Hits the Internet, Radiologists Get the First Look
Ultrafast Full-Body MRI Eases Procedure in Claustrophobics, Kids
WHO Melanoma Study: Interferon Boosts Disease-Free Survival
Coram to Purchase Caremark's Home Infusion Therapy Business
NCCR Unveils Six New Public Service TV Announcements
GAO Says Federal Research Needed on Safety of Portable Cellular Telephones
Breast Examination Center of Harlem Expands Service
Recent Videos
Related Content
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
